High Expression of CLEC11A Predicts Favorable Prognosis in Acute Myeloid Leukemia

Overview

Journal Front Oncol

Specialty Oncology

Date 2021 Mar 22

PMID 33747924

Citations 10

Authors

Chengliang Yin

Junyan Zhang

Wei Guan

Liping Dou

Yuchen Liu

Ming Shen

Xiaodong Jia

Lu Xu

Rilige Wu

Yan Li

Affiliations

Soon will be listed here.

Abstract

Background: Acute myeloid leukemia (AML) is a heterogeneous disease of the hematopoietic system, for which identification of novel molecular markers is potentially important for clinical prognosis and is an urgent need for treatment optimization.

Methods: We selected C-type lectin domain family 11, member A (CLEC11A) for study several public databases, comparing expression among a variety of tumors and normal samples as well as different organs and tissues. To investigated the relationship between CLEC11A expression and clinical characteristics, we derived an AML cohort from The Cancer Genome Atlas (TCGA); we also investigated the Bloodspot and HemaExplorer databases. The Kaplan-Meier method and log-rank test were used to evaluate the associations between CLEC11A mRNA expression, as well as DNA methylation, and overall survival (OS), event-free survival (EFS), and relapse-free survival (RFS). DNA methylation levels of CLEC11A from our own 28 AML patients were assessed and related to chemotherapeutic outcomes. Bioinformatics analysis of CLEC11A was carried out using public databases.

Results: Multiple public databases revealed that CLEC11A expression was higher in leukemia. The TCGA data revealed that high CLEC11A expression was linked with favorable prognosis (OS -value = 2e-04; EFS -value = 6e-04), which was validated in GSE6891 (OS -value = 0; EFS -value = 0; RFS -value = 2e-03). Methylation of CLEC11A was negatively associated with CLEC11A expression, and high CLEC11A methylation level group was linked to poorer prognosis (OS -value = 1e-02; EFS -value = 2e-02). Meanwhile, CLEC11A hypermethylation was associated with poor induction remission rate and dismal survival. Bioinformatic analysis also showed that CLEC11A was an up-regulated gene in leukemogenesis.

Conclusion: CLEC11A may be used as a prognostic biomarker, and could do benefit for AML patients by providing precise treatment indications, and its unique gene pattern should aid in further understanding the heterogeneous AML mechanisms.

Citing Articles

Characterization of ligand-receptor pair in acute myeloid leukemia: a scoring model for prognosis, therapeutic response, and T cell dysfunction.

Fu C, Qiu D, Zhou M, Ni S, Jin X Front Oncol. 2024; 14:1473048.

PMID: 39484036 PMC: 11525004. DOI: 10.3389/fonc.2024.1473048.

Machine learning-based biomarker screening for acute myeloid leukemia prognosis and therapy from diverse cell-death patterns.

Qin Y, Pu X, Hu D, Yang M Sci Rep. 2024; 14(1):17874.

PMID: 39090256 PMC: 11294352. DOI: 10.1038/s41598-024-68755-3.

CLEC11A methylation is correlated to AML subtypes and cytogenetic risk factors but not patient demographics.

Swanson A, Rogowski V, Bishop J, Walker D, Roxas G, Raimondi S PLoS One. 2024; 19(3):e0300477.

PMID: 38466706 PMC: 10927138. DOI: 10.1371/journal.pone.0300477.

Identification and characterization of CLEC11A and its derived immune signature in gastric cancer.

Zheng Q, Gong Z, Li B, Cheng R, Luo W, Huang C Front Immunol. 2024; 15:1324959.

PMID: 38348052 PMC: 10859539. DOI: 10.3389/fimmu.2024.1324959.

A machine learning model identifies M3-like subtype in AML based on PML/RARα targets.

Shao T, Li J, Su M, Yang C, Ma Y, Lv C iScience. 2024; 27(2):108947.

PMID: 38322990 PMC: 10844831. DOI: 10.1016/j.isci.2024.108947.

References

Sahin F, Kizilkilic E, Bulakbasi T, Yilmaz Z, Boga C, Ozalp O . Cytogenetic findings and clinical outcomes of adult acute myeloid leukaemia patients. Clin Exp Med. 2007; 7(3):102-7. DOI: 10.1007/s10238-007-0130-2. View

Khwaja A, Bjorkholm M, Gale R, Levine R, Jordan C, Ehninger G . Acute myeloid leukaemia. Nat Rev Dis Primers. 2016; 2:16010. DOI: 10.1038/nrdp.2016.10. View

Zhao X, Li Y, Wu H . A novel scoring system for acute myeloid leukemia risk assessment based on the expression levels of six genes. Int J Mol Med. 2018; 42(3):1495-1507. PMC: 6089755. DOI: 10.3892/ijmm.2018.3739. View

Berdasco M, Esteller M . Aberrant epigenetic landscape in cancer: how cellular identity goes awry. Dev Cell. 2010; 19(5):698-711. DOI: 10.1016/j.devcel.2010.10.005. View

Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik V, Paschka P, Roberts N . Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med. 2016; 374(23):2209-2221. PMC: 4979995. DOI: 10.1056/NEJMoa1516192. View

Bagger F, Rapin N, Theilgaard-Monch K, Kaczkowski B, Thoren L, Jendholm J . HemaExplorer: a database of mRNA expression profiles in normal and malignant haematopoiesis. Nucleic Acids Res. 2012; 41(Database issue):D1034-9. PMC: 3531225. DOI: 10.1093/nar/gks1021. View

Tomczak K, Czerwinska P, Wiznerowicz M . The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn). 2015; 19(1A):A68-77. PMC: 4322527. DOI: 10.5114/wo.2014.47136. View

Santos F, Jones D, Qiao W, Cortes J, Ravandi F, Estey E . Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia. Cancer. 2011; 117(10):2145-55. PMC: 4184429. DOI: 10.1002/cncr.25670. View

Leygo C, Williams M, Jin H, Chan M, Chu W, Grusch M . DNA Methylation as a Noninvasive Epigenetic Biomarker for the Detection of Cancer. Dis Markers. 2017; 2017:3726595. PMC: 5605861. DOI: 10.1155/2017/3726595. View

10.

Bhojwani D, Kang H, Moskowitz N, Min D, Lee H, Potter J . Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study. Blood. 2006; 108(2):711-7. PMC: 1895482. DOI: 10.1182/blood-2006-02-002824. View

11.

Prada-Arismendy J, Arroyave J, Rothlisberger S . Molecular biomarkers in acute myeloid leukemia. Blood Rev. 2016; 31(1):63-76. DOI: 10.1016/j.blre.2016.08.005. View

12.

Ito C, Sato H, Ando K, Watanabe S, Yoshiba F, Kishi K . Serum stem cell growth factor for monitoring hematopoietic recovery following stem cell transplantation. Bone Marrow Transplant. 2003; 32(4):391-8. DOI: 10.1038/sj.bmt.1704152. View

13.

Keller C, Ouma C, Ouma Y, Awandare G, Davenport G, Were T . Suppression of a novel hematopoietic mediator in children with severe malarial anemia. Infect Immun. 2009; 77(9):3864-71. PMC: 2737985. DOI: 10.1128/IAI.00342-09. View

14.

Medeiros B . Is there a standard of care for relapsed AML?. Best Pract Res Clin Haematol. 2018; 31(4):384-386. DOI: 10.1016/j.beha.2018.09.006. View

15.

Creutzig U, Kaspers G . Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2004; 22(16):3432-3. DOI: 10.1200/JCO.2004.99.116. View

16.

Li T, Fan J, Wang B, Traugh N, Chen Q, Liu J . TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res. 2017; 77(21):e108-e110. PMC: 6042652. DOI: 10.1158/0008-5472.CAN-17-0307. View

17.

Wouters B, Delwel R . Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia. Blood. 2015; 127(1):42-52. DOI: 10.1182/blood-2015-07-604512. View

18.

Kisiel J, Raimondo M, Taylor W, Yab T, Mahoney D, Sun Z . New DNA Methylation Markers for Pancreatic Cancer: Discovery, Tissue Validation, and Pilot Testing in Pancreatic Juice. Clin Cancer Res. 2015; 21(19):4473-81. PMC: 4592385. DOI: 10.1158/1078-0432.CCR-14-2469. View

19.

Bagger F, Sasivarevic D, Sohi S, Laursen L, Pundhir S, Sonderby C . BloodSpot: a database of gene expression profiles and transcriptional programs for healthy and malignant haematopoiesis. Nucleic Acids Res. 2015; 44(D1):D917-24. PMC: 4702803. DOI: 10.1093/nar/gkv1101. View

20.

Li Y, Zhao H, Xu Q, Lv N, Jing Y, Wang L . Detection of prognostic methylation markers by methylC-capture sequencing in acute myeloid leukemia. Oncotarget. 2018; 8(66):110444-110459. PMC: 5746395. DOI: 10.18632/oncotarget.22789. View